Top 50 ranked by Buffett-Fit
Sorted by composite quality score - ROIC, margin stability, balance-sheet strength, growth quality. Click any ticker for the full Buffett verdict.
Drug developers, gene therapy, mRNA platforms, diagnostics. Binary outcomes - patent + FDA risk dominate. Average ROIC negative because most pre-revenue names burn cash; the few winners compound aggressively.
Industry leader
Sunmax Biotechnology Co., Ltd. 4728.TWO
Buffett-Fit: 81/100
Biotechnology is the highest-variance industry in healthcare. Patent expirations are scheduled value destruction; FDA approvals are binary risk. The Buffett-Fit framework favours commercial-stage biotechs with sustained positive net income + clear pipeline depth - typically large-cap names rather than pre-revenue clinical-stage companies. Avoid the average; chase the winners.
Sorted by composite quality score - ROIC, margin stability, balance-sheet strength, growth quality. Click any ticker for the full Buffett verdict.
See all industries + sector-level statistics + framework filters.
Educational framework analysis only. Not investment advice, not a recommendation, not personalized to your situation. Always do your own research.
